LTR Secures Exclusive U.S. Pharmacy Partner for ROXUS
Filed with ASX · · 3 pages · English
Summary by 6ix AI
LTR Pharma Limited has secured an exclusive partnership with Strive Specialties Inc. for the pharmacy fulfilment of its product ROXUS in the United States, marking a significant step in its commercialization strategy. This agreement establishes the necessary infrastructure for supplying ROXUS, a rapid-acting intranasal treatment for erectile dysfunction, across various commercial channels. The partnership aims to enhance patient access and reduce risks associated with the product launch. The binding term sheet outlines key terms, including exclusivity and a two-year initial term for the partnership.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Story so far
Earlier from LTR Pharma
- LTR Secures First U.S. Commercial Agreement for ROXUS
- SPONTAN® Phase II interim data demonstrates rapid onset and pharmacokinetic profile addressing FDA Pre-IND requirements across adult and ≥65 populations
- SPONTAN Phase II data show rapid onset, support FDA pathway
- SPONTAN Phase II Clinical Study Completes Recruitment
- Appendix 4D and Half Yearly Report
Later from LTR Pharma
- Response to ASX Aware Letter
- LTR Executes Definitive U.S. Commercial Agreement with Shed
- LTR Executes U.S. Commercial Agreement with Strive
- SPONTAN Real-World Study Reports 93% Response
- FY26 Results Announcement
Follow LTR Pharma into a list and get an email when it puts out news.
Follow LTR Pharma